Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Neoplasms 2Triple Negative Breast Neoplasms 1Skin Diseases 1Prostatic Neoplasms 1Neoplasms by Site 1Breast Diseases 1

Interventions

ribociclib 2palbociclib 2Gonadotropin-Releasing Hormone 2Doxorubicin 2Docetaxel 2Anastrozole 2AZD9833 2trastuzumab deruxtecan 1taxane 1pertuzumab 1pegfilgrastim 1ipatasertib 1atezolizumab 1abemaciclib 1Trastuzumab 1Sodium Chloride 1Paclitaxel 1Letrozole 1Ibuprofen 1Fulvestrant 1Drug Therapy 1Denosumab 1Cyclophosphamide 1Codeine 1Capecitabine 1Botulinum Toxins, Type A 1Bevacizumab 1Acetaminophen 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Diseases × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡